23 Polyomaviruses (PyVs) can cause serious disease in immunosuppressed hosts. Several 24 pathogenic PyVs encode microRNAs (miRNAs), small RNAs that regulate gene expression 25 via RNA silencing. Despite recent advances in understanding the activities of PyV miRNAs, 26 the biological functions of PyV miRNAs during in vivo infections are mostly unknown. 27 Studies presented here use murine polyomavirus (MuPyV) as a model to assess the roles of 28 the PyV miRNAs in a natural host. This analysis reveals that a MuPyV mutant that is unable 29 to express miRNAs has enhanced viral DNA loads in select tissues at late times after 30 infection, indicating that during infection of a natural host, PyV miRNAs function to reduce 31 viral replication during the persistent phase of infection. Additionally, MuPyV miRNAs 32 promote viruria during the acute phase of infection as evidenced by a defect in shedding 33 during infection with the miRNA mutant virus. The viruria defect of the miRNA mutant 34 virus could be rescued by infecting Rag2-/-mice. These findings implicate miRNA activity 35 in both the persistent and acute phases of infection and suggest a role for MuPyV miRNA in 36 evading the adaptive immune response. 37 38 Importance 39 MicroRNAs are expressed by diverse viruses, but for only a few is there any understanding 40 of their in vivo function. PyVs can cause serious disease in immunocompromised hosts. 41 Therefore, increased knowledge of how these viruses interact with the immune response is 42 of possible clinical relevance. Here we show a novel activity for a viral miRNA in promoting 43 virus shedding. This work indicates that in addition to any role for the PyV miRNA in long-44 term persistence, that it also has biological activity during the acute phase. As this mutant 45 phenotype is alleviated by infection of mice lacking an effective adaptive immune response, 46 our work also connects the in vivo activity of a PyV miRNA to the immune response. Given 47 that PyV-associated disease is associated with alterations in the immune response, our 48 findings may help to better understand how the balance between PyV and the immune 49 response becomes altered in pathogenic states. 50 51 been the most tractable in vivo model for studying the PyV life cycle and has played an important 56 role in understanding PyV-mediated transformation and the antiviral response (2, 3, 4). MuPyV is 57
Introduction 52 53
The polyomavirus (PyV) family is comprised of a large number of viruses that predominantly 54 infect vertebrates (1) . The founding member of the PyVs, murine polyomavirus (MuPyV), has 55
In addition to regulating viral replication, independent studies implicate a role for the PyV 97 miRNAs in inhibiting the host immune response. Downregulation of T-antigen by the SV40 98 miRNAs decreases CD8 T-cell-mediated lysis in cell culture (16) . miRNA-mediated 99 downregulation of the host ULBP3 stress-induced ligand has been suggested to reduce killing of 100 BKV-and JCV-infected cells by natural killer cells (26). MuPyV miRNAs reduce Smad2-101 mediated apoptosis during infection (27) . These studies support a model whereby the PyV 102 miRNAs modulate viral and host transcripts in order to extend the life of infected cells by reducing 103 innate and adaptive immune responses. 
Sequencing of the MuPyV miRNAs 115
MuPyV miRNAs were initially identified via secondary structure predictions and confirmed 116 indirectly (17). This approach could only estimate the 5' and 3' termini of the derivative miRNAs. 117
It also did not resolve whether MuPyV contains additional miRNA loci. To better characterize the 118
MuPyV miRNAs, we conducted high throughput sequencing of small RNA from NIH3T3 cells 119 infected with the MuPyV PTA strain (Figure 1 ). These results map with precision the termini of 120 the MuPyV miRNAs and confirm that only the single, previously identified pre-miRNA locus, 121
gives rise to MuPyV-encoded miRNA derivatives. High virus yields (2 x 10 5 -5 x 10 6 genome equivalents/ug DNA) were observed in spleen and 135 kidney after one and four weeks of infection with PTA, consistent with robust virus replication 136 during the acute phase of replication ( Figure 2) . Lower levels were observed in liver during these 137 times ( Figure 2 ). Virus loads diminished to ≤ 10 3 genome equivalents/ug DNA at later times after 138 infection (16 and 28 weeks p.i.), consistent with a low level of virus replication during the 139 persistent phase of replication. These levels were only slightly above the limit of detection of our 140 PCR assay, even when increased input DNA was assayed. 141
142
In comparison to PTA, PTA-dl1013 levels were 4.1-fold lower in spleen, but not kidney, at one 143 week p.i. (Figure 2 , closed symbols). No significant differences in PTA and PTA-dl1013 DNA 144 levels were detected at 4 weeks or 10 weeks after infection. However, at 16 weeks, PTA-dl1013 145 genome levels were approximately 10-fold higher than PTA in spleen and kidney. By 28 weeks, 146 only low levels of both PTA and PTA-dl1013 genome levels were detected and no significant 147 differences were observed. These results confirm that the miRNAs are not required for infection 148 and replication in tissues during the acute phase of infection, and indicate that miRNA expression 149 correlates with reduced genomic DNA in certain tissues during the persistent phase of infection. 150
151
The results summarized in Figure 2 reveal a substantial variation in viral copies between different 152 mice. To minimize variations due to inter-host differences, we compared levels of PTA and PTA-153 dl1013 in individual animals. C57BL/6 mice were co-infected with equivalent amounts of PTA 154 and PTA-dl1013 by IP injection. Tissues were then harvested during the acute (2 and 4 weeks) and 155 persistent (10 and 16 weeks) phases of infection, and genome levels were determined by strain-156 specific qPCR (Supplemental Figure 1A -C). Similar to individually infected mice, we observed high levels of both PTA and PTA-dl1013 in tissues during the acute phase of infection, with 158
MuPyV levels decreasing during the persistent phase of infection ( Figure 3 ). We note that PTA 159 was not detected in the spleen or kidney by 16 weeks p.i., while PTA-dl1013 was present at 10 3 -160 10 4 copies/ug DNA (Figure 3 ). To compensate for variation in different animals, we calculated the 161 ratio of PTA to PTA-dl1013 genomes in individual mice. This analysis reveals that during the 162 acute phase of infection (2 and 4 weeks p.i.), the levels of PTA and PTA-dl1013 were comparable 163 in spleen and kidney (Figure 4 ). At later times, PTA-dl1013 copy numbers were 10-fold higher 164 than PTA in the spleen and kidney at weeks 10 and 16 and 100-fold higher in the kidney at week 165 16 ( Figure 4 ). We did not observe substantial differences in the liver, but did observe 7-fold higher 166 PTA-dl1013 in the bladder at week 4 ( Figure 4 ). These results are consistent with the elevated 167 levels of PTA-dl1013 detected in the spleen and kidney at 16 weeks following infections with the urine is considered a primary route of transmission (6,28). Therefore, we investigated whether the 176 MuPyV miRNAs affects the magnitude and/or frequency of MuPyV shedding in the urine during 177 the acute and persistent phases of infection. To test this, we collected urine specimens periodically 178 post-infection and quantitated viral genomes. To assess whether PTA-dl1013 could maintain long-term persistence, we treated mice with cyclosporine at day 474 post-infection in order to 180 immunosuppress the mice, which is correlated with increased PyV replication (4). 181
182
In the majority of mice individually infected with PTA or PTA-dl1013, we observed vDNA 183 shedding of both strains during the acute phase of infection (13-34 days p.i.) (Supplemental Figure  184 2), indicating that the MuPyV miRNAs are not required for establishing viruria. Both strains were 185 episodically shed throughout the persistent phase (34-87 day p.i.), which demonstrates that the 186 MuPyV miRNAs are not required for persistent viruria (Supplemental Figure 2 ). The magnitude 187 and timing of virus shedding by individual mice infected varied substantially (Supplemental Figure  188 2), and thus no statistical differences between PTA and PTA-dl1013 levels could be determined. 189
190
To circumvent the differences in shedding due to variations between individual mice, we tested 191 whether expression of miRNA could correlate with viral shedding in mice co-infected with both 192 PTA and PTA-dl1013. Adult C57BL/6 female mice were co-infected with equal amounts of the 193 PTA and PTA-dl1013, and PTA and PTA-dl1013 DNA was quantitated during the acute and 194 persistent phases of infection ( Figure 5A ). We did not detect substantial quantities of either PTA 195 or PTA-dl1013 genomes in the urine of ~40% of the mice at any time point during the acute phase 196 of infection (Supplemental file). The remaining "high-shedder" mice expressed readily detectable 197
MuPyV DNA in the urine. MuPyV in these samples was detected at high levels beginning by 10 198 days p.i. and peaked between 13-27 days, after which the number of shedding mice and the 199 magnitude of shedding began to decrease. Thereafter, we observed episodic shedding events 200 throughout the persistent phase of infection (34-87 days p.i.). These findings reveal that while some mice rarely or never shed detectable virus under our assay conditions, ~60% that are 202 competent for acute and persistent viruria. 203
204
The median PTA levels were significantly higher (5-to 100-fold) than PTA-dl1013 during the 205 majority of the acute phase of infection (10, 13 . 15, 17, 20 and 27 days p.i.) in co-infected mice 206 ( Figure 5A ). To minimize the variance in individual mice, we determined the ratio of PTA:PTA-207 dl1013 DNA in each individual mouse. This data confirmed that PTA was shed at significantly 208 higher levels on average (~10-fold) than PTA-dl1013 during days 10-17 of the acute phase of 209 infection in individual mice co-infected mice ( Figure 5B ). We did not observe statistically 210 significant differences in the magnitude of viral shedding at the majority of times tested during the 211 persistent phase of infection ( Figure 5A , 5B, Supplemental file). Although this may be due to high 212 variance in the timing and the magnitude of shedding, as well as the lower number of mice tested, 213 this suggests that the MuPyV miRNAs do not promote viruria during the persistent phase of 214 infection. In fact, we observed eighty-four PTA-dl1013 shedding events that were above the limit 215 of detection from days 34 through 87, compared to thirty-three for PTA ( Figure 5A ). This implies 216 that the MuPyV miRNAs may limit detectable shedding during persistent phase of infection, were found to continually increase in the co-infected C57BL/6 Rag2-/-mice up to 20 days p.i., 239
whereas MuPyV levels leveled off and began to decrease by 20 days p.i. ( Figure 6 ). These 240 observations are consistent with the host adaptive immune response being a major factor that 241 controls MuPyV shedding. Importantly, unlike in wild type C57BL/6 mice, C57BL/6 Rag2-/-mice 242
shed PTA-dl1013 DNA at levels similar to PTA during the acute phase of infection (10-13 days 243 p.i.) ( Figure 6 ). These data indicate that the MuPyV miRNAs promote viruria during the acute 244 phase of infection in a manner that is dependent on the host having an intact adaptive immune 245 response. The exact mechanism(s) by which MuPyV miRNA expression enhances virus shedding in 295 immunocompetent mice remains unclear. Because we observed miRNA-dependent promotion of 296 shedding in co-infected immunocompetent mice, this indicates that MuPyV miRNAs are likely 297 functioning via a cell autonomous mechanism to repress the effects of the adaptive immune 298 response. This is consistent with previous findings that the SV40 miRNAs can reduce CD8 T-cell-299 mediated lysis. However, it is unclear why the miRNAs promote viruria only during a narrow 300 window of time post-infection. One possibility is that the MuPyV miRNAs increase dissemination 301 to the target cells required for subsequent viruria, possibly by reducing the CTL response to 302 promote infection/replication in lymphocytes early during the acute phase of infection. In support 303 of this, at one week p.i., but not at 2 and 4 weeks p.i., we observed ~4-fold higher PTA DNA levels 304 specifically in the spleen (Figures 2-4 The PTA and PTA-dl1013 virus strains have been described previously (17). Virus was propagated 332 by infecting primary BMK cells (80% confluent) with PTA or PTA-dl1013 at an MOI of 0.05. 333
Virus stocks were prepared after 10 days by scraping the cells into a portion of the culture medium. 334
The cell extracts were then subjected to three freeze/thaw cycles, clarified by centrifugation, and 335 stored at -80°C. 336 337 Virus titers were determined by immunofluorescence. 80-90% confluent NIH3T3 cells in 12-or 338 24-well plates were infected with dilutions of the PTA and PTA-dl1013 virus stocks for one hour. 339
Infected cells were maintained in DMEM+2% FBS for 40 hours and then fixed and permeabilized 340 with 4% paraformaldehyde and 1% NP-40. After blocking with 10% goat serum overnight, cells 341
were incubated with rabbit-anti-PyV antibody (a gift from Dr. Richard Consigi) for 30 min. After 342 three PBS washes, cells were stained with Cy3-goat-anti-rabbit IgG (Abcam) for 10 min. and washed. The numbers of total and stained cells per field were quantified by using an inverted 344 fluorescent microscope (Leica), and infectious titers (IU/ml) were determined. 345 346
Animal infections and tissue analysis 347
Female C57BL/6 (Jackson Laboratories) and C57BL/6 Rag2-/-mice were inoculated with 1 x 10 5 348 IU of either PTA or PTA-dl1013 via intraperitoneal (IP) injection between 4 and 5 weeks of age. 349 CTCCGGTTCCATTGGCATGT-NFQ). The PTA and PTAdl1013 standards (10 7 /ul -10 1 /ul) were 380 confirmed by using the universal MuPyV primers/probe, which detects both PTA and PTA-381 dl1013, to ensure that the copy number of each standard was equal. Assays were performed using 382 384-well format plates in a ViiA™ 7 Real-Time PCR System (Applied Biosystems). The limit of 383 detection was 10 copies. 384 385
Statistical analyses 386
One sample T-test (two-tailed) and Mann-Whitney U-test (two-tailed) were performed using real 387 statistics resource package for excel (http://www.real-statistics.com/). normalization. Samples that were below the limit of detection are graphed at the limit of detection. qPCR analysis of PTA and PTA-dl1013 genome levels in the spleen, kidney, liver, and bladder of 499 adult C57BL/6 mice inoculated with 5x10 4 IUs of PTA and 5x10 4 IUs of PTA-dl1013 via IP 500 injection. Tissues were harvested at indicated time points. DNA was recovered and subject to 501 qPCR analysis using PTA-and PTA-dl1013-specific probes. The limit of detection (L.O.D.) was 502 10 copies. Samples in which PTA or PTA-dl1013 were below the limit of detection were graphed 503 at the limit of detection. The quantities were normalized to 1-ug of total DNA. P-values were 504 determined using Mann-Whitney U test. 505 The ratio of PTA and PTA-dl1013 genome copies from (A) in the indicated organs of individual 507 mice co-infected with PTA and PTA-dl1013. Values below the limit of detection were set at the 508 limit of detection. The dots represent Log 10 (PTA/PTA-dl1013). P-values were calculated using 509 one-sample t-test. 510 Mice were co-infected with 5x10 4 IU of PTA and 5x10 4 IU of PTA-dl1013 via IP injection, urine 512 samples were collected at the indicated times, and strain-specific qPCR was used to quantify wt 513 and mutant genomes. The number of mice tested at each time ranged from 18-30 mice during days 514 1-27 p.i., 10-20 mice during days 29-55 p.i., and 4 mice during days 62-492 p.i. Panel A presents 515 a dot plot of genome equivalents of PTA (blue circles) and PTA-dl1013 (yellow triangles) in 2 ul 516 of urine from mice that shed viral genome copies equal to or greater that the limit of detection of 517 the qPCR assay. Mice that did not shed above the limit of detection or time points in which 518 genomes were not detected were not included in this analysis. Lines represent the median values of PTA (solid blue) and PTA-dl1013) (dotted yellow). Significant differences (P ≤ 0.05) between 520 PTA and PTA-dl1013 genome levels are marked by asterisks. Panel B compares the ratio of wt 521 and mutant genomes in individual mice co-infected with PTA and PTA-dl1013. When only one 522 genome could be detected (either PTA or PTA-dl1013), the other genome was set at the limit of 523 detection in order to calculate the PTA/PTA-dl1013 ratio. The line represents the average 524 log10(PTA/PTA-dl1013) ± SEM. P values were calculated by using a one sample t-test (asterisks 525 indicate P ≤ 0.05). 526 6  8  10  13  15  17  20  22  24  27  29  31  34  36  38  41  43  45  48  51  55  58  62  66  69  73  76  80  83  84  87  467  469  471  474  476  478  481  483  485  488  490 
